摘要
目的:系统评价氯吡格雷与阿托伐他汀联合应用对缺血性心脑血管疾病的影响。方法:以"clopidogrel"、"atorvastatin"、"ClinicalTrial"、"氯吡格雷"、"阿托伐他汀"、"临床试验"为检索词,分别在EMBase、PubMed、Cochrane图书馆和中国期刊网数据库(CNKI)4个中英文数据库中进行检索,用ReviewManager5.0软件进行数据分析。结果:共有5项研究被纳入,以氯吡格雷为对照的相关临床研究有4篇(n=5874),以阿托伐他汀为对照的相关临床研究有3篇(n=6790)。结果显示,(1)氯吡格雷与阿托伐他汀联合应用时,心肌梗死、脑卒中和缺血性死亡综合事件的发生率比单独使用氯吡格雷低39%(合并RR=0.61,95%C(I0.51～0.74))。(2)氯吡格雷与阿托伐他汀联合应用时,综合终点事件发生率比单独使用阿托伐他汀低19%(合并RR=0.81,95%CI为(0.71～0.93))。结论:在临床上,氯吡格雷与阿托伐他汀的联合应用存在协同效应,比单独应用氯吡格雷或阿托伐他汀对缺血事件的预防作用更强。
OBJECTIVE：To investigate the effects of clopidogrel plus atorvastatin on ischemic cardiovascular diseases and to explore the clinical significance of drug interactions.METHODS：Literatures were retreived from EMBase,PubMed,Cochrane Library and CNKI with clopidogrel,atorvastatin,clinical trial as
出处
《中国药房》
CAS
CSCD
北大核心
2010年第24期2283-2286,共4页
China Pharmacy
关键词
氯吡格雷
阿托伐他汀
缺血性心脑血管疾病
系统评价
in English and Chinese.A meta-analysis was performed using Review Manager 5.0 system.RESULTS：A total of 5 trials were included
involving 4 literatures were about clopidogrel clinical study（n=5 874） and 3 literuatures of atorvastatin clinical study（n=6 790）.The incidence of myocardial infraction
cerebral apoplexy
ischemic death in the therapy of clopidogrel combined with atorvastatin was 39% lower than that in the therapy of clopidgrel alone（overall RR=0.61
95%CI：0.51～0.74）.The incidence of ischemic cardiovascular diseases in the therapy of clopidogrel combined with atorvastatin was 19% lower than that in the therapy of clopidgrel alone（overall RR=0.81
95%CI：0.71~0.93）.CONCLUSION：A synergistic interaction between clopidogrel and atorvastatin is found in the clinic.The therapy of clopidogrel combined with atorvastatin is better than clopidogrel or atorvastatin alone in preventing ischemic cardiovascular diseases. KEY WORDS Clopidogrel
Atorvastatin
Ischemic cardiovascular diseases
Systemaintic evaluation
